Gemcitabine/Dexamethasone/Cisplatin vs Cytarabine/Dexamethasone/Cisplatin for Relapsed or Refractory Aggressive-Histology Lymphoma: Cost-Utility Analysis of NCIC CTG LY.12-Reference-Cited by-同舟云学术

Gemcitabine/Dexamethasone/Cisplatin vs Cytarabine/Dexamethasone/Cisplatin for Relapsed or Refractory Aggressive-Histology Lymphoma: Cost-Utility Analysis of NCIC CTG LY.12

Published:2015-04-13 Issue:7 Volume:107 Page:
ISSN:1460-2105
Container-title:JNCI: Journal of the National Cancer Institute
language:en
Short-container-title:

Author:

Cheung Matthew C.,Hay Annette E.,Crump Michael,Imrie Kevin R.,Song Yuyao,Hassan Shazia,Risebrough Nancy,Sussman Jonathan,Couban Stephen,MacDonald David,Kukreti Vishal,Kouroukis C. Tom,Baetz Tara,Szwajcer David,Desjardins Pierre,Shepherd Lois,Meyer Ralph M.,Le Al,Chen Bingshu E.,Mittmann Nicole

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/107/7/djv106/17314622/djv106.pdf

Reference31 articles.

1. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma;N Engl J Med,1995

2. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin’s lymphoma;J Clin Oncol,1999

3. Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience;Hematol Oncol Clin North Am,1997

4. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era;J Clin Oncol,2010

5. Randomized comparison of Gemcitabine, dexamethasone, cisplatin versus dexamethasone, cytarabine, cisplatin chemotherapy before autologous stem cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG study LY.12;J Clin Oncol,2014

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chidamide plus R‐GDP for relapsed/refractory diffuse large B‐cell lymphoma in patients ineligible for autologous transplantation: A prospective, single‐arm, phase II study;Cancer Medicine;2024-08

2. Ibrutinib Plus RCHOP versus RCHOP Only in Young Patients with Activated B-Cell-like Diffuse Large B-Cell Lymphoma (ABC-DLBCL): A Cost-Effectiveness Analysis;Current Oncology;2023-12-15

3. Power and sample size calculation for incremental net benefit in cost effectiveness analyses with applications to trials conducted by the Canadian Cancer Trials Group;BMC Medical Research Methodology;2023-08-03

4. Contact Days Associated With Cancer Treatments in the CCTG LY.12 Trial;The Oncologist;2023-05-25

5. Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma;Journal of Clinical Oncology;2023-03-10